Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd. develops and commercializes enzymatic, non-surgical therapies for tissue repair as a global biotechnology company. Its FDA-approved biologic NexoBrid is indicated for enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets.
News about MDWD commonly covers financial results, corporate updates, NexoBrid commercialization and distribution, BARDA-supported burn-care activity, and the development of EscharEx, an investigational bromelain-based therapy for debridement of chronic and hard-to-heal wounds. Company updates also include clinical data presentations, wound-care conference activity, regulatory filings, and shareholder communications.
MediWound Ltd. (NASDAQ: MDWD) announced its Q1 2022 financial results, reporting revenues of $4.4 million, a 24% decline from $5.8 million in Q1 2021. The company faced a 56% drop in product revenue, primarily due to decreased emergency stockpile procurement by BARDA. Despite a net loss of $3.6 million or $0.12 per share, MediWound highlighted the positive results from its U.S. Phase 2 trial of EscharEx®, achieving primary and secondary endpoints with no safety issues. The company has raised $10 million through equity offerings and is on track for NexoBrid BLA resubmission by mid-year.
MediWound Ltd. (Nasdaq: MDWD) has announced positive results from its U.S. Phase 2 clinical study of EscharEx® for treating venous leg ulcers (VLUs). The study met its primary and key secondary endpoints with statistically significant improvements, including a 63% complete debridement rate in 14 days versus 30% for the control. EscharEx demonstrated a median time to complete debridement of 9 days compared to 59 days for standard care. The FDA meeting is anticipated in the second half of 2022 to discuss advancing to Phase 3 trials. No safety issues were observed, reinforcing EscharEx's therapeutic potential.
MediWound Ltd. (Nasdaq: MDWD) will announce its first-quarter financial results on May 17, 2022. The release will be followed by a conference call at 8:30 AM ET for management to discuss these results and provide corporate updates. MediWound specializes in bio-therapeutic solutions for tissue repair, notably its product NexoBrid for thermal burns, which has received support from BARDA. The company is also developing EscharEx for chronic wounds and MW005 for non-melanoma skin cancers. The webcast will be accessible for 90 days following the call.
MediWound Ltd. (Nasdaq: MDWD) announced that its EscharEx® phase 2 clinical study results were featured at the SAWC Spring Conference. The poster highlighting the pharmacology study was among ten selected from 235 presented. The data indicated EscharEx effectively debrided wounds and reduced biofilm while being safe for patients with diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). CEO Sharon Malka expressed optimism about EscharEx's potential in the over billion-dollar wound care market, emphasizing the urgent need for new debridement solutions.
MediWound Ltd. (Nasdaq: MDWD) announced the presentation of its EscharEx® clinical data at the 35th SAWC Spring Conference in April 2022. The oral presentation will cover results from clinical studies on the safety and efficacy of EscharEx for the debridement of hard-to-heal wounds, including venous leg ulcers and diabetic foot ulcers. The data showed that EscharEx was well-tolerated and effectively reduced biofilm and bacterial loads. The ongoing Phase 2 study aims to evaluate its clinical performance, positioning EscharEx as a potential non-surgical treatment for chronic wounds.
MediWound Ltd. (Nasdaq: MDWD) announced the partial exercise of an over-allotment option from its recent public offering, closing on March 22, 2022. The underwriter purchased an additional 623,082 ordinary shares, raising approximately $1.2 million. This brings the total funds raised in the offering to $11.2 million. MediWound plans to utilize the proceeds for working capital and corporate purposes. The offering was conducted under a previously filed shelf registration statement with the SEC.
MediWound Ltd. (Nasdaq: MDWD) has completed its U.S. Phase 2 clinical study of EscharEx for treating venous leg ulcers (VLUs). The study met its primary endpoint, showing a significant improvement in complete debridement rates: 63% for EscharEx versus 30% for the gel vehicle (p=0.004). Final results, including secondary safety measurements, are expected in Q2 2022. CEO Sharon Malka emphasized EscharEx's potential as a leading solution for chronic wound care, aiming to advance to pivotal Phase 3 trials.
MediWound Ltd. (MDWD) reported total revenues of $23.8 million for 2021, reflecting a 9% increase from 2020, with product revenues soaring 46% to $11.4 million. The company achieved profitability for its NexoBrid product but faced an 18% decline in Q4 revenues to $5.5 million. A public equity offering garnered an additional $10 million. Positive results from the Phase 2 EscharEx trial support its potential for chronic wound treatment, and FDA guidance indicates a path for the NexoBrid Biologics License Application resubmission in mid-2022.
MediWound Ltd. (Nasdaq: MDWD) announced the closure of its public offering of 5,208,333 ordinary shares at $1.92 per share, raising approximately $10 million. The underwriters received a 30-day option for an additional 781,249 shares. The funds will be used for working capital and corporate purposes. Notable investors include Clal Biotechnology Industries, the largest shareholder. This offering utilized a shelf registration statement declared effective by the SEC in April 2019.
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for Q4 and the year ending December 31, 2021, on March 17, 2022. Following this, a conference call will take place at 8:30 AM ET, allowing management to discuss results and corporate updates. MediWound focuses on bio-therapeutic solutions for tissue repair, including NexoBrid®, a product for burn care, currently marketed in the EU and at the registration stage in the U.S., and EscharEx®, a topical treatment for chronic wounds. The company's strategy emphasizes innovation in improving patient care.